AGI offers validated inflammatory and metabolic disease platforms that replicate complex human pathophysiology, providing sponsors with clinically relevant models to evaluate candidate therapeutics. Our capabilities include diet-induced obesity, insulin resistance, and non-alcoholic steatohepatitis (NASH) models that accurately reflect human metabolic disease progression. These models are enhanced by advanced biomarker panels, metabolic imaging, glucose and lipid profiling, and histopathology to capture systemic and organ-specific effects. We integrate longitudinal sampling and multi-parametric analysis, allowing for the detailed assessment of therapeutic efficacy on chronic inflammation, metabolic dysregulation, and associated comorbidities.

 

Sponsors benefit from translational insights that inform target validation, mechanism-of-action studies, and dose–response relationships. By generating reproducible data that bridges preclinical findings with anticipated clinical outcomes, Alpha Genesis supports regulatory submissions and accelerates the development of therapies in endocrinology, hepatology, cardiometabolic health, and related fields. With scalable study design, regulatory-aligned reporting, and advanced analytical platforms, our inflammatory and metabolic programs provide the precision and depth required to bring novel therapeutics closer to patients while reducing risk and development timelines.